| Trial ID: | L6240 |
| Source ID: | NCT01995656
|
| Associated Drug: |
Placebo - Capsule
|
| Title: |
A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo - Capsule|DRUG: LY3108743 - Capsule|DRUG: Placebo - Solution|DRUG: LY3108743 - Solution
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, Pre-dose up to Day 6 (5 days post-dose) | Secondary: Maximum Change from Baseline up to 24 Hours in Level of Blood Glucose Before and After a Standard Meal, Baseline up to 24 hours|Pharmacokinetics: Maximum Concentration (Cmax) of LY3108743, Baseline up to 48 hours|Pharmacokinetics: Area Under the Curve (AUC) of LY3108743, Baseline up to 48 hours
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
44
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2013-12
|
| Completion Date: |
2014-04
|
| Results First Posted: |
|
| Last Update Posted: |
2014-07-15
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, 117597, Singapore
|
| URL: |
https://clinicaltrials.gov/show/NCT01995656
|
